How to Manage ISRs That Occur With Injectable Agents in Psoriasis

Slides:



Advertisements
Similar presentations
INTRODUCTION TO TOXICOLOGY SIDNEY GREEN, PH.D. DEPARTMENT OF PHARMACOLOGY COLLEGE OF MEDICINE HOWARD UNIVERISTY.
Advertisements

Extended duration of injection interval. 2 Lucas et al. Efficacy of lanreotide Autogel ® administered every 4–8 weeks in patients with acromegaly previously.
Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.
Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Introduction to Direct-to-Consumer Genetic Testing
INTRODUCTION The oral route of drugs administration is the most important method of administering drugs for systemic effects.
Introduction to Biosimilars
Evolution of Treatment Strategies Targeting IL-23 for Psoriasis
IL-12 and IL-23.
Why Gene Therapy for Hemophilia?
Why New Treatments for Schizophrenia Should Be on Your Radar
Pharmaceutical- vs Dispensary-Sourced Cannabinoids
Panelists. Panelists Drug-Coated Balloon for PAD.
Optimizing Use of Biological Agents in Ulcerative Colitis
New Patient-Friendly Options for Managing Insulin Dosing
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Understanding the Many Faces of Pseudobulbar Affect
Metastatic Renal Cell Carcinoma
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Optimizing the Treatment of Recurrent/Metastatic SCCHN
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Definitions: Seizure, Epilepsy, Epilepsy Syndrome
Management Considerations in Epilepsy Among Long-Term Care Residents

Oral Anticoagulants in AFa,b A Brief History.
Optimizing Patient Outcomes in IBD
Chronic Idiopathic Urticaria
Improving Surgical Outcomes
Minding the Gap Rheumatoid Arthritis Advances From London 2016
Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?
Improving Outcomes in OSA
Next-Gen Psoriasis Therapies:
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Biosimilars in Hematologic Oncology
A Primer on Medication Delivery Systems in COPD Management
Biotherapeutics.
CGRP Antibodies in Migraine
Perspectives on the Impact of Inflammation in OA
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Impactful Data in TD That Can Guide Treatment Decisions
Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.
Advancing the Treatment of IBD With Biologics
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
New Data on Emerging Treatments for Psoriasis
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration 
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
A Primer on Medication Delivery Systems in COPD Management
Advances in Immunotherapy for Peanut Allergy
Advancing Patient Care in RA
Implications of Emerging Treatments for Beta-Thalassemia
The Rising Cost of Healthcare and Potential Impact of Biosimilars
The Burden of Psoriasis:
Patient Questions and Expert Answers in Psoriasis:
Critical Decision Points in Insomnia
ҚАЗАҚСТАН РЕСПУБЛИКАСЫНДА САБАҚТЫ ЗЕРТТЕУ ТӘСІЛІН ІСКЕ АСЫРУ
Managing Anemia in Lower-Risk MDS
From Adjuvant to Metastatic in Melanoma
AMD Therapy: Where Are We Now and Where Are We Going?
HAE Prophylaxis.
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Lethal Agents Introduction.
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
Safety and PK of Subcutaneous GS-6207, a Novel HIV-1 Capsid Inhibitor
Gail A. Van Norman BTS 2016;1: Time, Money, and Success: Stages in Drug Development The highest failure rates occurs in Phase II testing, which.
New Options for the Treatment of Hepatocellular Carcinoma
Panelists. Panelists Drug-Coated Balloon for PAD.
Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.
Navigating the Journey
Women With Psoriasis Are Struggling More Than Men
Presentation transcript:

How to Manage ISRs That Occur With Injectable Agents in Psoriasis

Introduction

MOA and Dosing of Approved Biologics Administered Via SC Injection

Efficacy of Approved Biologics Administered Via SC Injection

ISRs: How Do They Manifest and When Do They Occur?

Potential Factors Leading to Occurrence of ISRs

ISRs: Incidence, Duration, and Time Course

Practical Considerations for Reducing the Impact of ISRs and Their Management

Impact of Different Drug Delivery Approaches on ISRs

Conclusions

Abbreviations